Concepts (194)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 38 | 2025 | 2586 | 2.730 |
Why?
|
| Brain | 6 | 2024 | 1472 | 1.360 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2020 | 247 | 1.160 |
Why?
|
| Monocytes | 10 | 2024 | 277 | 1.120 |
Why?
|
| Cerebral Cortex | 5 | 2017 | 306 | 1.090 |
Why?
|
| Atrophy | 4 | 2024 | 51 | 1.060 |
Why?
|
| DNA, Viral | 3 | 2014 | 311 | 1.050 |
Why?
|
| AIDS Dementia Complex | 5 | 2024 | 116 | 0.990 |
Why?
|
| Dementia, Vascular | 2 | 2023 | 35 | 0.970 |
Why?
|
| Magnetic Resonance Imaging | 11 | 2025 | 587 | 0.960 |
Why?
|
| Prefrontal Cortex | 2 | 2018 | 164 | 0.960 |
Why?
|
| Depression | 3 | 2024 | 863 | 0.860 |
Why?
|
| Oxidative Phosphorylation | 2 | 2020 | 60 | 0.770 |
Why?
|
| Anti-HIV Agents | 13 | 2021 | 486 | 0.730 |
Why?
|
| Nerve Net | 2 | 2025 | 101 | 0.710 |
Why?
|
| Male | 45 | 2025 | 23409 | 0.640 |
Why?
|
| Electrocardiography | 2 | 2017 | 185 | 0.620 |
Why?
|
| Heart Rate | 2 | 2017 | 266 | 0.600 |
Why?
|
| Mitochondria | 2 | 2020 | 523 | 0.590 |
Why?
|
| Mitochondrial Proteins | 1 | 2019 | 118 | 0.580 |
Why?
|
| Alzheimer Disease | 2 | 2023 | 1001 | 0.560 |
Why?
|
| Cross-Sectional Studies | 14 | 2024 | 3156 | 0.550 |
Why?
|
| Neural Pathways | 1 | 2018 | 138 | 0.540 |
Why?
|
| Middle Aged | 32 | 2025 | 12222 | 0.540 |
Why?
|
| Aging | 8 | 2024 | 783 | 0.530 |
Why?
|
| Cognition | 8 | 2024 | 473 | 0.530 |
Why?
|
| Sympathetic Nervous System | 1 | 2017 | 57 | 0.520 |
Why?
|
| Humans | 49 | 2025 | 43102 | 0.510 |
Why?
|
| Cognition Disorders | 5 | 2022 | 243 | 0.490 |
Why?
|
| Hippocampus | 3 | 2025 | 594 | 0.490 |
Why?
|
| Deoxyguanosine | 1 | 2016 | 36 | 0.480 |
Why?
|
| Viral Load | 6 | 2021 | 348 | 0.460 |
Why?
|
| Longitudinal Studies | 8 | 2024 | 1063 | 0.460 |
Why?
|
| Prospective Studies | 7 | 2024 | 1600 | 0.460 |
Why?
|
| HIV-1 | 9 | 2024 | 755 | 0.450 |
Why?
|
| Anti-Retroviral Agents | 6 | 2018 | 160 | 0.430 |
Why?
|
| DNA, Mitochondrial | 1 | 2016 | 191 | 0.430 |
Why?
|
| Female | 36 | 2025 | 24698 | 0.400 |
Why?
|
| Cerebellum | 1 | 2013 | 79 | 0.390 |
Why?
|
| Aged, 80 and over | 5 | 2024 | 2853 | 0.340 |
Why?
|
| Adult | 19 | 2025 | 13872 | 0.340 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2024 | 279 | 0.330 |
Why?
|
| Organ Size | 3 | 2020 | 170 | 0.330 |
Why?
|
| Inflammation | 5 | 2018 | 758 | 0.320 |
Why?
|
| Antiretroviral Therapy, Highly Active | 6 | 2023 | 229 | 0.300 |
Why?
|
| Central Nervous System Diseases | 2 | 2019 | 32 | 0.300 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 2 | 2018 | 22 | 0.290 |
Why?
|
| Antigens, CD | 2 | 2018 | 127 | 0.280 |
Why?
|
| Receptors, Cell Surface | 2 | 2018 | 146 | 0.280 |
Why?
|
| Thailand | 2 | 2020 | 51 | 0.270 |
Why?
|
| Hawaii | 7 | 2024 | 2011 | 0.270 |
Why?
|
| Central Nervous System | 2 | 2018 | 152 | 0.270 |
Why?
|
| Risk Factors | 10 | 2023 | 3994 | 0.270 |
Why?
|
| Aged | 8 | 2024 | 8214 | 0.260 |
Why?
|
| Gyrus Cinguli | 2 | 2025 | 31 | 0.260 |
Why?
|
| Neuropsychological Tests | 6 | 2024 | 284 | 0.260 |
Why?
|
| CD4 Lymphocyte Count | 4 | 2021 | 201 | 0.250 |
Why?
|
| Hypertension | 2 | 2023 | 835 | 0.240 |
Why?
|
| Cardiovascular Diseases | 3 | 2020 | 749 | 0.230 |
Why?
|
| Insulin Resistance | 2 | 2020 | 201 | 0.230 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2024 | 184 | 0.220 |
Why?
|
| Corpus Striatum | 1 | 2025 | 121 | 0.220 |
Why?
|
| RNA, Viral | 4 | 2020 | 321 | 0.210 |
Why?
|
| Longevity | 2 | 2023 | 173 | 0.200 |
Why?
|
| Lipoproteins | 2 | 2014 | 70 | 0.200 |
Why?
|
| Asia | 1 | 2023 | 98 | 0.200 |
Why?
|
| Educational Status | 2 | 2023 | 339 | 0.190 |
Why?
|
| Vitamin D | 2 | 2016 | 196 | 0.190 |
Why?
|
| Follow-Up Studies | 2 | 2024 | 1067 | 0.190 |
Why?
|
| Apolipoprotein E2 | 1 | 2022 | 6 | 0.190 |
Why?
|
| Diabetes Mellitus | 3 | 2020 | 539 | 0.190 |
Why?
|
| Caudate Nucleus | 2 | 2012 | 22 | 0.190 |
Why?
|
| Oxidative Stress | 2 | 2019 | 1003 | 0.180 |
Why?
|
| Caenorhabditis elegans | 1 | 2022 | 80 | 0.180 |
Why?
|
| Cerebrovascular Disorders | 2 | 2012 | 43 | 0.180 |
Why?
|
| Receptors, CCR5 | 2 | 2018 | 64 | 0.170 |
Why?
|
| Bone Diseases | 1 | 2020 | 18 | 0.160 |
Why?
|
| Cyclohexanes | 2 | 2023 | 30 | 0.160 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2019 | 18 | 0.160 |
Why?
|
| Interferon Regulatory Factors | 1 | 2019 | 18 | 0.160 |
Why?
|
| Autoantibodies | 1 | 2021 | 117 | 0.160 |
Why?
|
| Electron Transport Complex IV | 1 | 2019 | 41 | 0.160 |
Why?
|
| Myeloid Cells | 1 | 2019 | 31 | 0.150 |
Why?
|
| Oxidoreductases | 1 | 2019 | 79 | 0.150 |
Why?
|
| Triazoles | 2 | 2023 | 102 | 0.150 |
Why?
|
| Stroke | 1 | 2023 | 340 | 0.150 |
Why?
|
| Erythrocyte Indices | 1 | 2018 | 14 | 0.150 |
Why?
|
| Benzoxazines | 1 | 2018 | 47 | 0.140 |
Why?
|
| Viremia | 1 | 2018 | 44 | 0.140 |
Why?
|
| Galectins | 1 | 2018 | 30 | 0.140 |
Why?
|
| Cohort Studies | 3 | 2019 | 1759 | 0.140 |
Why?
|
| Receptors, CCR2 | 1 | 2018 | 28 | 0.140 |
Why?
|
| Rest | 1 | 2018 | 32 | 0.140 |
Why?
|
| Erythrocytes | 1 | 2018 | 126 | 0.140 |
Why?
|
| Pilot Projects | 3 | 2018 | 760 | 0.130 |
Why?
|
| Atherosclerosis | 2 | 2016 | 169 | 0.130 |
Why?
|
| Brain Injuries | 1 | 2018 | 129 | 0.130 |
Why?
|
| Bilirubin | 1 | 2016 | 18 | 0.120 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 386 | 0.120 |
Why?
|
| Carotid Artery Diseases | 1 | 2016 | 26 | 0.120 |
Why?
|
| Serum Amyloid P-Component | 1 | 2015 | 21 | 0.120 |
Why?
|
| Brachial Artery | 1 | 2015 | 27 | 0.120 |
Why?
|
| Lymphocyte Activation | 3 | 2024 | 249 | 0.120 |
Why?
|
| Vasodilation | 1 | 2015 | 64 | 0.120 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2014 | 301 | 0.110 |
Why?
|
| Coronary Vessels | 1 | 2016 | 92 | 0.110 |
Why?
|
| Chemokine CCL2 | 1 | 2016 | 95 | 0.110 |
Why?
|
| Young Adult | 3 | 2021 | 5080 | 0.110 |
Why?
|
| Ferrosoferric Oxide | 1 | 2013 | 13 | 0.100 |
Why?
|
| Polyneuropathies | 1 | 2013 | 9 | 0.100 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2013 | 12 | 0.100 |
Why?
|
| Reflex | 1 | 2013 | 29 | 0.100 |
Why?
|
| DNA Damage | 1 | 2016 | 356 | 0.100 |
Why?
|
| Social Work | 1 | 2013 | 53 | 0.100 |
Why?
|
| Niacin | 1 | 2013 | 23 | 0.100 |
Why?
|
| Calcium | 1 | 2016 | 491 | 0.100 |
Why?
|
| Albuminuria | 1 | 2013 | 78 | 0.100 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 532 | 0.100 |
Why?
|
| Cytokines | 1 | 2016 | 678 | 0.090 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2014 | 226 | 0.090 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 107 | 0.090 |
Why?
|
| Amphetamine-Related Disorders | 1 | 2012 | 69 | 0.090 |
Why?
|
| Macrophages | 2 | 2013 | 529 | 0.090 |
Why?
|
| Acne Vulgaris | 1 | 2011 | 7 | 0.090 |
Why?
|
| Cacao | 1 | 2011 | 10 | 0.090 |
Why?
|
| HIV Seropositivity | 1 | 2013 | 196 | 0.090 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2011 | 58 | 0.090 |
Why?
|
| Retrospective Studies | 3 | 2016 | 2544 | 0.090 |
Why?
|
| Pregnancy Complications | 1 | 2012 | 140 | 0.080 |
Why?
|
| Attention | 1 | 2012 | 174 | 0.080 |
Why?
|
| AIDS-Associated Nephropathy | 1 | 2010 | 14 | 0.080 |
Why?
|
| Methamphetamine | 1 | 2012 | 166 | 0.080 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2012 | 192 | 0.080 |
Why?
|
| Genotype | 2 | 2023 | 800 | 0.080 |
Why?
|
| CD4-CD8 Ratio | 2 | 2020 | 29 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2013 | 925 | 0.070 |
Why?
|
| Case-Control Studies | 3 | 2018 | 1285 | 0.070 |
Why?
|
| Leukocyte Count | 2 | 2018 | 69 | 0.060 |
Why?
|
| Smoking | 1 | 2012 | 1024 | 0.060 |
Why?
|
| Immunophenotyping | 2 | 2016 | 57 | 0.060 |
Why?
|
| Incidence | 2 | 2023 | 1078 | 0.050 |
Why?
|
| Receptors, Immunologic | 1 | 2024 | 73 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 719 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2023 | 21 | 0.050 |
Why?
|
| Age Factors | 2 | 2018 | 1154 | 0.050 |
Why?
|
| Phenotype | 2 | 2016 | 780 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 183 | 0.050 |
Why?
|
| Apolipoprotein E4 | 1 | 2022 | 67 | 0.040 |
Why?
|
| Apolipoproteins E | 1 | 2022 | 138 | 0.040 |
Why?
|
| Alleles | 1 | 2022 | 352 | 0.040 |
Why?
|
| Blood Glucose | 2 | 2014 | 389 | 0.040 |
Why?
|
| Autoantigens | 1 | 2021 | 87 | 0.040 |
Why?
|
| HIV | 1 | 2020 | 100 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2021 | 259 | 0.040 |
Why?
|
| Uganda | 1 | 2019 | 22 | 0.040 |
Why?
|
| Neopterin | 1 | 2018 | 13 | 0.040 |
Why?
|
| Cyclopropanes | 1 | 2018 | 46 | 0.040 |
Why?
|
| Alkynes | 1 | 2018 | 52 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2023 | 863 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 1 | 2020 | 209 | 0.040 |
Why?
|
| Macrophage Activation | 1 | 2018 | 61 | 0.030 |
Why?
|
| Calcinosis | 1 | 2016 | 62 | 0.030 |
Why?
|
| Receptors, IgG | 1 | 2014 | 53 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 245 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2014 | 46 | 0.030 |
Why?
|
| Disease Management | 1 | 2014 | 70 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2014 | 91 | 0.030 |
Why?
|
| Zidovudine | 1 | 2013 | 32 | 0.030 |
Why?
|
| Comorbidity | 1 | 2016 | 737 | 0.020 |
Why?
|
| Prognosis | 1 | 2016 | 861 | 0.020 |
Why?
|
| Disease Progression | 1 | 2016 | 667 | 0.020 |
Why?
|
| Occipital Lobe | 1 | 2012 | 5 | 0.020 |
Why?
|
| Delayed-Action Preparations | 1 | 2013 | 74 | 0.020 |
Why?
|
| Seasons | 1 | 2013 | 139 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 113 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2013 | 259 | 0.020 |
Why?
|
| Frontal Lobe | 1 | 2012 | 58 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2015 | 549 | 0.020 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2012 | 27 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2014 | 863 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 440 | 0.020 |
Why?
|
| Gene Expression | 1 | 2014 | 701 | 0.020 |
Why?
|
| Psychological Tests | 1 | 2011 | 56 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 2012 | 159 | 0.020 |
Why?
|
| Marijuana Abuse | 1 | 2012 | 100 | 0.020 |
Why?
|
| Memory | 1 | 2012 | 174 | 0.020 |
Why?
|
| Cell Movement | 1 | 2013 | 655 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 259 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2013 | 1604 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2012 | 1546 | 0.020 |
Why?
|
| Pregnancy | 1 | 2012 | 1772 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2012 | 661 | 0.010 |
Why?
|
| Animals | 1 | 2022 | 16992 | 0.010 |
Why?
|
| Adolescent | 1 | 2011 | 6081 | 0.010 |
Why?
|